SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Acadia Pharmaceuticals beats Q3 expectations with $342M revenue, raising DAYBUE guidance to $505M-$520M and announcing a new patent extension and FDA Fast Track designation for rem…
Tenaya announced regulatory biomarker for heart disease and provided business updates ahead of quarterly data. The stock is expected to react to key interim trial results and pivot…
Institutional holdings report (13F-HR) for the period ended 2026-09-30 filed by Marathon Wealth Advisors LLC.
Institutional holdings report (13F-HR) for the period ended 2026-09-30 filed by EQUITEC PROPRIETARY MARKETS, LLC.
Institutional holdings report (13F-HR) for the period ended 2026-09-30 filed by ACCOUNT MANAGEMENT LLC.
Caris Life Sciences reported a 27% revenue increase to $275.4 million for Q3 2026, surpassing prior-year performance in molecular profiling services and raising full-year revenue g…
Progyny surpassed expectations with record Q3 revenue and gross profit, while maintaining high client retention. The company raised its full-year guidance amid strong momentum and …
Institutional holdings report (13F-HR) for the period ended 2026-09-30 filed by Atlas Merchant Capital LLC.
Institutional holdings report (13F-HR) for the period ended 2026-09-30 filed by Blue Water Asset Management.
The company reported an increase in Core FFO and rent growth, while also repurchasing shares in the third quarter.
Institutional holdings report (13F-HR) for the period ended 2026-09-30 filed by DBA TRADING, LLC.
Paycom reported strong third-quarter earnings and raised its full-year revenue outlook. The cloud-based HCM software provider sees revenue growth of roughly 8% for 2026.
Sera Prognostics announced Q3 2026 revenue of $42,000, driven by a 54% sequential increase in PreTRM test volume and the addition of Florida Medicaid coverage. The company stated t…
HubSpot reported third-quarter 2026 revenue of $947.6 million, up 17%, driven by subscription growth. The company also updated its 2026 guidance.
Relay Therapeutics reported $849 million in cash and announced ongoing Phase 3 trial enrollment progress for breast cancer. The company also provided an update regarding an upcomin…
Institutional holdings report (13F-HR) for the period ended 2026-09-30 filed by ARCH CAPITAL GROUP LTD..
Institutional holdings report (13F-HR) for the period ended 2026-09-30 filed by NEW YORK LIFE INVESTMENT MANAGEMENT LLC.
Institutional holdings report (13F-HR) for the period ended 2026-09-30 filed by Gen-Wealth Partners Inc.
Mineralys reported 46% of patients met AHA guidelines in Launch-HTN at Week 12. The positive data bolsters investor confidence ahead of a key FDA decision for its hypertension drug…
Institutional holdings report (13F-HR) for the period ended 2026-09-30 filed by Clientfirst Wealth Management, LLC.